JANX PEER ANALYSIS

Janux Therapeutics Inc — metric-by-metric comparison with peers and the industry median

JANXJanux Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

JANXIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	JANX	MSB	TLX	RTALB	CSL	Ind. Median
P/E	—	—	—	4.89●	30.02	17.81
P/B	1.03	—	6.56	0.61●	2.24	3.49
EV/EBITDA	—	—	123.31	74.61	10.37●	14.92
P/S	44.68	31.91	3.34	6.67	2.67●	10.89

Financial Health
Metric	JANX	MSB	TLX	RTALB	CSL	Ind. Median
Current Ratio	17.01●	—	1.43	1.21	2.57	5.90
Debt/Equity	2.3%	—	112.3%	1.2%●	67.4%	10.9%
NetDebt/EBITDA	8.31	—	13.13	0.90●	2.22	1.15

Profitability
Metric	JANX	MSB	TLX	RTALB	CSL	Ind. Median
Net Margin	-529.7%	-115.3%	-0.9%	136.3%●	9.2%	-125.7%
ROE	-11.7%	-11.3%	-1.8%	15.1%●	7.7%	-47.5%
ROA	-11.0%	-8.6%	-0.7%	13.1%●	3.8%	-35.8%
EBITDA Margin	-520.3%	-76.6%	3.0%	9.0%	32.8%●	-105.8%

Growth + Dividend
Metric	JANX	MSB	TLX	RTALB	CSL	Ind. Median
Rev. Growth	2,522.9%●	410.4%	56.3%	24.0%	4.8%	5.1%
NI Growth	—	—	—	134.0%●	-39.4%	12.1%
Div. Yield	—	0.0%	—	0.0%	2.5%●	0.2%
Payout	—	0.0%	—	0.0%	103.1%	0.0%

Valuation
Metric	JANX	KURA	DSGN	ABUS	LXRX	PHAT	Ind. Median
P/E	—	—	—	6.04	—	—	17.81
P/B	1.03	9.07	4.18	3.73	4.58	-2.77●	3.49
EV/EBITDA	—	—	—	5.44	—	—	14.92
P/S	44.68	13.66	—	5.07	13.33	4.56●	10.89

Financial Health
Metric	JANX	KURA	DSGN	ABUS	LXRX	PHAT	Ind. Median
Current Ratio	17.01	6.15	22.28	54.26●	18.79	2.21	5.90
Debt/Equity	2.3%	22.5%	1.3%	0.2%	28.4%	-49.4%●	10.9%
NetDebt/EBITDA	8.31	1.90	3.19	-0.59●	6.48	0.16	1.15

Profitability
Metric	JANX	KURA	DSGN	ABUS	LXRX	PHAT	Ind. Median
Net Margin	-529.7%	-411.2%	—	84.0%●	-37.5%	-76.8%	-125.7%
ROE	-11.7%	-124.7%	-31.3%	94.7%●	-16.0%	—	-47.5%
ROA	-11.0%	-42.2%	-29.8%	81.5%●	-9.2%	-52.5%	-35.8%
EBITDA Margin	-520.3%	-408.0%	—	84.0%●	-25.0%	-44.4%	-105.8%

Growth + Dividend
Metric	JANX	KURA	DSGN	ABUS	LXRX	PHAT	Ind. Median
Rev. Growth	2,522.9%	5.4%	-100.0%	2,889.9%●	123.1%	150.3%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on JANX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.